KAS
IMNM icon

Kemnay Advisory Services’s Immunome IMNM Stock Holding History

Kemnay Advisory Services’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4K Buy
964
+115
+14% +$2.46K ﹤0.01% 726
2026
Q1 		$18.6K Buy
+849
New +$18.9K ﹤0.01% 734

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Kemnay Advisory Services's IMNM Position: Q2 2026 in Review

Kemnay Advisory Services increased its Immunome (IMNM) stake by 14% in Q2 2026, buying an estimated $2.46K and bringing the position to 964 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #726.

Kemnay Advisory Services first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Kemnay Advisory Services held 964 shares of Immunome worth $20.4K as of Q2 2026.
  • Kemnay Advisory Services bought 115 Immunome shares in Q2 2026, an estimated $2.46K.
  • Immunome made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #726 holding.
  • Kemnay Advisory Services first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.